AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38478488
Drug: Maintain serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintain serum potassium ≥ 3.6 mEq/L
Trial: 38478488
Drug: Maintain serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintain serum potassium ≥ 4.5 mEq/L
Trial: 38478705
Drug: mRNA-1647 (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1647 (30, 90, 180, or 300 µg)
Trial: 38479114
Drug: Combined 6-day
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combined 6-day program of exercise, self-management workshops, and spa therapy
Trial: 38479192
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) ketamine infusions (3 during acute phase, 4 additional if remitted)
Trial: 38479748
Drug: SMC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMC with directly observed treatment (DOT) for the full course in under 5-year-old children
Trial: 38479748
Drug: SMC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMC with directly observed treatment (DOT) for the full course in under 10-year-old children
Trial: 38479748
Drug: SMC without
RxNorm normalized name: prosolv SMCC 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMC without directly observed treatment (DOT) for the full course in under 5-year-old children
Trial: 38479803
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy followed by interval cytoreductive surgery
Trial: 38479953
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group using a conventional manual or automatic injection syringe (n=274)
Trial: 38480590
Drug: CYP2C19 genotype-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2C19 genotype-based personalized antiplatelet therapy; specific dosage and duration not mentioned.
Trial: 38480590
Drug: Standard antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiplatelet therapy without genotype information; specific details not mentioned.
Trial: 38480632
Drug: Preoperative 500
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative 500 mL fluid bolus
Trial: 38481147
Drug: Web-based surveillance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based surveillance and respiratory specimen collection kits; participants monitored weekly for respiratory illness symptoms and collected specimens at symptom onset.
Trial: 38481209
Drug: sirolimus 2
RxNorm normalized name: sirolimus 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sirolimus 2 mg once a day for a maximum of 60 months
Trial: 38481318
Drug: Manual therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapies (specific type not detailed)
Trial: 38481666
Drug: Triptorelin pamoate
RxNorm normalized name: Triptorelin Pamoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin pamoate (LHRH agonist)
Trial: 38481947
Drug: Pevonedistat in
RxNorm normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pevonedistat in combination with ruxolitinib
Trial: 38482462
Drug: CM326 55
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM326 55 mg every two weeks (Q2W)
Trial: 38482462
Drug: CM326 110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM326 110 mg every two weeks (Q2W)
Trial: 38482462
Drug: CM326 220
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM326 220 mg every two weeks (Q2W)
Trial: 38482462
Drug: CM326 220
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM326 220 mg every four weeks (Q4W)
Trial: 38483145
Drug: 36-week steroid
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 36-week steroid stepwise reduction (SSR)
Trial: 38483145
Drug: 48-week steroid
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 48-week steroid stepwise reduction (SSR)
Trial: 38483248
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral vitamin D3 (VD3) for 6 weeks
Trial: 38483309
Drug: Anlotinib (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib (12 mg orally once daily from days 1 to 14 every 3 weeks)
Trial: 38483458
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who reported plans to initiate or adjust medications.
Trial: 38483534
Drug: COVID-19 convalescent
RxNorm normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 convalescent plasma (CCP) transfusion with high antibody levels (upper 30% of study donors' antibody levels)
Trial: 38483782
Drug: Selumetinib 100
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib 100 mg plus Pembrolizumab 200 mg
Trial: 38483782
Drug: Selumetinib 125
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib 125 mg plus Pembrolizumab 200 mg
Trial: 38483782
Drug: Selumetinib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (various doses) plus Pembrolizumab
Trial: 38484130
Drug: c-Jun N-Terminal
RxNorm normalized name: CCK C-terminal octapeptide
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: c-Jun N-Terminal Kinase Inhibitor
Trial: 38484251
Drug: 5 mL/5
RxNorm normalized name: Mineral Oil 2.5 ML/5 ML Oral Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL/5 injection
Trial: 38484251
Drug: 10 mL/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL/10 injection
Trial: 38484756
Drug: Extended postnatal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended postnatal prophylaxis with lamivudine syrup twice per day for 12 months or 1 month after breastfeeding discontinuation, initiated based on maternal viral load measured using Xpert HIV viral load assay.
Trial: 38484853
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dry needling (DN) and spinal manipulative therapy (SMT)
Trial: 38484853
Drug: Spinal manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulative therapy (SMT) only
Trial: 38484976
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (1.9 g/d n-3 PUFAs)
Trial: 38485054
Drug: Intravenous furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous furosemide (40 mg)
Trial: 38485184
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg) administered every 2 weeks until disease progression, unacceptable toxicity, or for 24 months
Trial: 38485189
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks (2 mg/kg up to 200 mg for pediatric patients)
Trial: 38485210
Drug: Polypill (fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill (fixed-dose combination therapy including two antihypertensive agents, a statin, and aspirin)
Trial: 38485490
Drug: Opioid replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid replacement therapy (ORT) with benzodiazepine (BZD) coprescription
Trial: 38485490
Drug: Opioid replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid replacement therapy (ORT) alone
Trial: 38486179
Drug: Telemedicine-based follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemedicine-based follow-up with individual treatment plan, computer tablets, and home telemonitoring devices.
Trial: 38486776
Drug: Two-dose primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose primary series of ancestral strain vaccine
Trial: 38486776
Drug: Monovalent Beta
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent Beta variant booster vaccine
Trial: 38486776
Drug: Ancestral or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ancestral or variant strain booster vaccine
Trial: 38488388
Drug: Prenatal exposure
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal exposure to second-generation antipsychotics
Trial: 38489057
Drug: Chloroprocaine 3%
RxNorm normalized name: chloroprocaine 3% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroprocaine 3% Gel
Trial: 38489060
Drug: Aflibercept treatment
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept treatment
Trial: 38490057
Drug: Topotecan (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (0.75 mg/m²) and Paclitaxel (TP)
Trial: 38490057
Drug: Topotecan (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (0.75 mg/m²) and Cisplatin (TC)
Trial: 38490230
Drug: Stepped collaborative
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stepped collaborative care (once-weekly cognitive behavioural therapy for 50-60 min via telemedicine)
Trial: 38490230
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (screening and referral to a health-care provider for treatment of symptoms)
Trial: 38490532
Drug: 50 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g/d prune
Trial: 38490532
Drug: 100 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g/d prune
Trial: 38490660
Drug: LSALT peptide
RxNorm normalized name: LSALT Peptide
DrugBank: LSALT Peptide (DB16472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSALT peptide 5 mg intravenously daily for up to 14 days
Trial: 38491111
Drug: Durable polymer
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durable polymer drug-eluting stents (DP-DESs)
Trial: 38491111
Drug: Biodegradable polymer
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biodegradable polymer drug-eluting stents (BP-DESs)
Trial: 38491429
Drug: hs-CRP <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-CRP < 1.0 mg/L
Trial: 38491429
Drug: hs-CRP ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-CRP ≥ 1.0 mg/L
Trial: 38491559
Drug: GBC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBC plus nicotine metabolism-informed care (MIC)
Trial: 38491795
Drug: Benralizumab 10/30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab 10/30 mg according to weight (<35/≥35 kg)
Trial: 38492010
Drug: 2 L-polyethylene
RxNorm normalized name: polyethylenes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L-polyethylene glycol/ascorbate (2 L-PEG/Asc)
Trial: 38492157
Drug: Pembrolizumab ±
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab ± chemotherapy
Trial: 38493021
Drug: Avutometinib, FAK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avutometinib, FAK inhibitor defactinib, and their combination
Trial: 38493055
Drug: Neuromuscular blocking
RxNorm normalized name: Neuromuscular blocking agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromuscular blocking agents (n=281; 60%)
Trial: 38493055
Drug: Antibiotics (n=118;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (n=118; 25%)
Trial: 38493055
Drug: Cefazolin (52%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (52% of antibiotic-related reactions)
Trial: 38493088
Drug: Emollient therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emollient therapy (not specified dosage or duration)
Trial: 38493832
Drug: Aficamten 5-15
RxNorm normalized name: Aficamten
DrugBank: Aficamten (DB18490)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aficamten 5-15 mg once daily for 10 weeks
Trial: 38493953
Drug: Glutamine oral
RxNorm normalized name: glutamine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine oral suspension
Trial: 38494157
Drug: Intermittent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent dosing regimens of cefoxitin
Trial: 38494157
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of cefoxitin
Trial: 38494380
Drug: Androgen annihilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen annihilation therapy (AAT; leuprolide, abiraterone acetate plus prednisone, and apalutamide) plus metastasis-directed stereotactic body radiotherapy (SBRT) for 6 months
Trial: 38494412
Drug: MVA-BN-WEV vaccine
RxNorm normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-BN-WEV vaccine (2 doses, 4 weeks apart)
Trial: 38494525
Drug: Bacillus clausii
RxNorm normalized name: BACILLUS CLAUSII
DrugBank: Bacillus clausii (DB16537)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus clausii spore probiotics (LiveSpo CLAUSY; 2 billion CFU/5 mL ampoule) at high dosages of 4-6 ampoules a day
Trial: 38494526
Drug: Irreversible electroporation
RxNorm normalized name: Adult allogeneic CD4+ and CD8+ enriched T cells transduced with an anti-CD19 chimeric antigen receptor (CAR) that is site-specific integrated into the cellular genome. Adult allogeneic CD4+ and CD8+ enriched T cells, gene edited through the electroporati
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irreversible electroporation (IRE) after 3-month neo-adjuvant chemotherapy.
Trial: 38494571
Drug: Dapagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10 mg/day) with lifestyle education
Trial: 38494574
Drug: Tirzepatide (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide (various doses)
Trial: 38494597
Drug: Durvalumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab plus concurrent chemoradiotherapy (cCRT) with cisplatin
Trial: 38494847
Drug: Lu AF82422
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lu AF82422 (75, 225, 750, 2250, 4500, and 9000 mg for cohorts A1-A6; 2250 and 9000 mg for cohorts B1 and B2)
Trial: 38495608
Drug: Aripiprazole lauroxil
RxNorm normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aripiprazole lauroxil (AL) treatment (441mg, 662mg, or 882mg every 4 weeks or 882mg every 6 weeks) for six months
Trial: 38495608
Drug: Aripiprazole lauroxil
RxNorm normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aripiprazole lauroxil (AL) treatment
Trial: 38496619
Drug: Dasatinib plus
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib plus quercetin (senolytic treatment)
Trial: 38497241
Drug: BI 690517
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 690517 40 mg
Trial: 38497241
Drug: BI 690517
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 690517 (all doses)
Trial: 38497241
Drug: BI 690517
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 690517 10 mg
Trial: 38498030
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT)-based smoking cessation smartphone app, 4 weeks intervention
Trial: 38498084
Drug: Obinutuzumab (G)
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab (G) in combination with CHOP (G-CHOP)
Trial: 38498139
Drug: Risankizumab 150
RxNorm normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 150 mg (subcutaneous)
Trial: 38498142
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg CM-chitosan (KioMedine)
Trial: 38498141
Drug: Placebo (inactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (inactive drug) followed by Risankizumab 150 mg
Trial: 38498835
Drug: PPOS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPOS with oral micronized progesterone (200 mg from stimulation Day 1)
Trial: 38499015
Drug: Subcutaneous ND0612
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous ND0612 (levodopa-carbidopa 60.0/7.5 mg/mL)
Trial: 38499015
Drug: Oral levodopa-carbidopa
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral levodopa-carbidopa
Trial: 38499015
Drug: Subcutaneous ND0612
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous ND0612
Trial: 38499238
Drug: NTM-PD progression
RxNorm normalized name: Poly Hist PD
DrugBank: Thonzylamine (DB11235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTM-PD progression (defined as initiation of treatment or clinician's intention to treat)
Trial: 38499323
Drug: Bolus volume
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus volume of 10-20 mL/kg
Trial: 38499323
Drug: Exclusive administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exclusive administration of balanced crystalloids at 1 hour
Trial: 38499323
Drug: Exclusive administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exclusive administration of balanced crystalloids at 24 hours
Trial: 38499943
Drug: EOI block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EOI block with 40 ml 0.25% bupivacaine after anesthesia induction
Trial: 38500190
Drug: Pharmacist-facilitated medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-facilitated medication reviews with feedback on medication issues and recommendations to physicians.
Trial: 39282907
Drug: Ponsegromab 100
RxNorm normalized name: Ponsegromab
DrugBank: Ponsegromab (DB18943)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponsegromab 100 mg
Trial: 39282907
Drug: Ponsegromab 200
RxNorm normalized name: Ponsegromab
DrugBank: Ponsegromab (DB18943)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponsegromab 200 mg
Trial: 39282907
Drug: Ponsegromab 400
RxNorm normalized name: Ponsegromab
DrugBank: Ponsegromab (DB18943)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponsegromab 400 mg
Trial: 38500476
Drug: Zandelisib 60
RxNorm normalized name: Zandelisib
DrugBank: Zandelisib (DB18245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zandelisib 60 mg on Days 1-7 plus zanubrutinib 80 mg twice daily continuously in 28-day cycle
Trial: 38500841
Drug: 14-day bismuth
RxNorm normalized name: bismuth subcitrate 14 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day bismuth quadruple therapy
Trial: 38501082
Drug: Cultural Formulation
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cultural Formulation Interview (CFI) administered in the intervention group
Trial: 38501087
Drug: Adapted Internet-Delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted Internet-Delivered Cognitive Behaviour Therapy (ICBT) program
Trial: 38501087
Drug: Non-adapted Internet-Delivered
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adapted Internet-Delivered Cognitive Behaviour Therapy (ICBT) program
Trial: 38501219
Drug: Mivavotinib 80
RxNorm normalized name: Mivavotinib
DrugBank: Mivavotinib (DB16849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivavotinib 80 mg once-daily plus nivolumab 3 mg/kg on days 1 and 15 in 28-day cycles
Trial: 38501219
Drug: Mivavotinib 80
RxNorm normalized name: Mivavotinib
DrugBank: Mivavotinib (DB16849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivavotinib 80 mg plus nivolumab 3 mg/kg
Trial: 38501262
Drug: Niraparib maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib maintenance treatment
Trial: 38501946
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue photodynamic therapy (MB-PDT) performed after percutaneous abscess drainage with laser illumination at a fluence rate of 20 mW/cm.
Trial: 38501946
Drug: Standard-of-care abscess
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care abscess management including image-guided percutaneous drainage and antibiotics.
Trial: 38501980
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline and placebo capsules (Control)
Trial: 38502056
Drug: Bisoprolol (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (dose not specified)